We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ULTA:NASDAQUlta Beauty, Inc. Analysis

Data as of 2026-05-27 - not real-time

$507.35

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ulta Beauty is trading at $507.35, which sits below its 20‑day (≈$511.6), 50‑day (≈$525.9) and 200‑day (≈$567.2) moving averages, signaling a short‑term bearish price bias. The RSI of 44.9 suggests momentum is neutral, while the MACD histogram is positive, giving a modest bullish signal amid a broader downtrend. Volatility is elevated at roughly 30% over the past 30 days and the beta of ~0.62 points to lower systematic risk, but the stock’s price is roughly 25% above the DCF‑derived fair value of $405, indicating it may be overvalued on a cash‑flow basis.
Fundamentally, Ulta delivers solid top‑line growth (≈12% YoY) and exceptional profitability (ROE ~44%, operating margin ~12%). The balance sheet shows a high debt‑to‑equity ratio (~78%) offset by strong cash generation (free cash flow ~$0.9B). Analyst sentiment is bullish, with a recent Bank of America upgrade to “Buy” and a price target near $685, and the new YipitData partnership promises sharper merchandising insights. These drivers support a medium‑ to long‑term upside thesis despite the current technical weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below key moving averages indicating bearish bias
  • Positive MACD histogram offering limited upside
  • Support level near $469 providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst upgrade and $685 price objective
  • Robust revenue growth and high ROE
  • Strategic YipitData partnership enhancing merchandising

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained brand positioning in specialty beauty
  • Strong cash flow generation despite elevated debt
  • Long‑term upside potential reflected in analyst target median of $705

Key Metrics & Analysis

Financial Health

Revenue Growth11.80%
Profit Margin9.31%
P/E Ratio19.8
ROE43.59%
ROA14.74%
Debt/Equity77.83
P/B Ratio8.0
Op. Cash Flow$1.5B
Free Cash Flow$900.1M

Technical Analysis

TrendBearish
RSI44.9
Support$469.00
Resistance$543.21
MA 20$511.62
MA 50$525.92
MA 200$567.24
MACDBullish
VolumeStable
Fear & Greed Index92.34

Valuation

Fair Value$405.33
Target Price$681.50
Upside/Downside34.33%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.62
Volatility29.07%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.